Light Chain Bioscience

http://www.novimmune.com/

Last activity: 23.11.2018

Active

Categories: BrandDevelopmentLifeResearch

The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.

Mentions

Overview

Employees

51-200

Total raised

$88.21M

Founded date

1998

Funding Rounds 2

Date	Series	Amount	Investors
Sign up to see	Sign up to see	Sign up to see	Sign up to see
Dec 17, 2010	Series B round	$20.69M

Mentions in press and media 22

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Aug 23, 2018	Novimmune’s lead drug on the way to the market
Jul 23, 2018	Swedish company to acquire Novimmune’s emapalumab assets
Jul 4, 2018	Novimmune to receive up to $185M milestone payments
Apr 4, 2018	Novimmune submits first medicine for marketing approval
Dec 6, 2016	Novimmune signed second agreement with Genentech
May 11, 2016	Novimmune raises additional CHF30 million
May 11, 2016	Novimmune raises CHF 30M in second financing of 2016	Novimmune has raised money for the second time in 5 months. The latest CHF 30 million ($31 million) investment brings the total raised in 2016 up to CHF 60 million, a sum Novimmune plans to use to hustle its treatment for the immune disorde...
Jan 12, 2016	Novimmune Completes CHF30 Million Funding Round
Sep 2, 2015	Success for Novimmune’s new antibody platform
Dec 29, 2014	Tiziana Life Sciences licenses foralumab from Novimmune
Aug 7, 2014	Novimmune reports successful completion of Phase I trial for NI-0101
Mar 21, 2014	Novimmune appoints experienced CFO
Feb 20, 2014	Novimmune Closes 60M CHF Series B	GENEVA, SWITZERLAND, Novimmune has closed a 60 million CHF Series B round of funding. >> Click here for more funding data on Novimmune >> To export Novimmune funding data to PDF and Excel, click here Novimmune SA announce...
Feb 18, 2014	Novimmune banks $66M for immunotherapies as IPO rumors surface	Swiss biotech Novimmune has closed a $66 million B round to bankroll its broad pipeline of monoclonal antibodies, and one of the company's lead investors told a local newspaper that it's considering going public to further finance its proje...
Feb 18, 2014	Novimmune announces closing of CHF 60 million financing
Feb 18, 2014	Novimmune Closes CHF60M Series B Financing	Novimmune SA, a Geneva, Switzerland-based drug discovery and development company, closed a CHF60m (approximately $66m) Series B financing. The round was led by London-based Rosetta Capital Limited with participation from new private investo...
Nov 30, 2012	NovImmune initiates Phase I clinical study with a new antibody
Oct 15, 2012	EUR 6 million grant for project led by Novimmune
Apr 26, 2012	Seven Swiss Companies among the Red Herring Top 100 Europe
Sep 22, 2011	NovImmune Initiates a Proof-of-Concept Study
Dec 17, 2010	NovImmune Raises CHF20M in Series B Financing	NovImmune, a Geneva, Switzerland-based drug discovery and development company with a focus on therapeutic monoclonal antibodies (mAbs) for inflammatory diseases and immune-related disorders, has raised CHF 20m in Series B financing. The rou...

Reviews 0

FAQ about Light Chain Bioscience

When was Light Chain Bioscience founded?

Light Chain Bioscience was founded in 1998.

How much funding has Light Chain Bioscience raised?

Light Chain Bioscience has raised $88.21M in total across 2 funding rounds.

What funding rounds has Light Chain Bioscience raised?

Parsers VC lists 2 funding rounds of Light Chain Bioscience, among them a Series B round of $20.69M on Dec 17, 2010.

What has the press written about Light Chain Bioscience?

Parsers VC has collected 22 articles mentioning Light Chain Bioscience, among them “Novimmune’s lead drug on the way to the market” (Aug 23, 2018) and “Swedish company to acquire Novimmune’s emapalumab assets” (Jul 23, 2018).

Is Light Chain Bioscience still active?

Yes, Light Chain Bioscience is active; its latest activity on Parsers VC dates from Nov 23, 2018.